相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Development of a PDEδ-Targeting PROTACs that Impair Lipid Metabolism
Michael Winzker et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)
INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models
Phillip C. C. Liu et al.
PLOS ONE (2020)
Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6
Baishan Jiang et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2019)
Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions
Johannes Popow et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
TAS-120 Overcomes Resistance to ATP-Compartitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholanjiocarcinoma
Lipika Goyal et al.
CANCER DISCOVERY (2019)
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Y. Loriot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4
Xiaojing Lin et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Fibroblast growth factor receptor inhibitors: patent review (2015-2019)
Giuseppe Marseglia et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2019)
Bruton tyrosine kinase degradation as a therapeutic strategy for cancer
Dennis Dobrovolsky et al.
BLOOD (2019)
TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure
Maria Kalyukina et al.
CHEMMEDCHEM (2019)
Fibroblast growth factor receptors as treatment targets in clinical oncology
Masaru Katoh
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
Calla M. Olson et al.
NATURE CHEMICAL BIOLOGY (2018)
Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor
Yujun Zhao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations
Sumanta K. Pal et al.
CANCER DISCOVERY (2018)
Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting
Brendan Farrell et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2018)
A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader
Hai-Tsang Huang et al.
CELL CHEMICAL BIOLOGY (2018)
Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application
Young Kwang Chae et al.
ONCOTARGET (2017)
An overview of the binding models of FGFR tyrosine kinases in complex with small molecule inhibitors
Weiyan Cheng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors
Ken A. Brameld et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Targeted Protein Degradation: from Chemical Biology to Drug Discovery
Philipp M. Cromm et al.
CELL CHEMICAL BIOLOGY (2017)
Cooperative binding mitigates the high-dose hook effect
Ranjita Dutta Roy et al.
BMC SYSTEMS BIOLOGY (2017)
FGFR a promising druggable target in cancer: Molecular biology and new drugs
Rut Porta et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Michael Zengerle et al.
ACS CHEMICAL BIOLOGY (2015)
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nintedanib: From Discovery to the Clinic
Gerald J. Roth et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Genomic spectra of biliary tract cancer
Hiromi Nakamura et al.
NATURE GENETICS (2015)
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
Kenneth S. Thress et al.
NATURE MEDICINE (2015)
Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma
Yasuhito Arai et al.
HEPATOLOGY (2014)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors
Li Tan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4
Jyothsna Gattineni et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2014)
Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
Fabrice Andre et al.
CLINICAL CANCER RESEARCH (2013)
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
Yi-Mi Wu et al.
CANCER DISCOVERY (2013)
AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
Paul R. Gavine et al.
CANCER RESEARCH (2012)
Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
Joseph M. Gozgit et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase
Vito Guagnano et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
A Structure-Guided Approach to Creating Covalent FGFR Inhibitors
Wenjun Zhou et al.
CHEMISTRY & BIOLOGY (2010)
Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant
Wei-Sheng Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Design, Structure-Activity Relationships and in Vivo Characterization of 4-Amino-3-benzimidazol-2-ylhydroquinolin-2-ones: A Novel Class of Receptor Tyrosine Kinase Inhibitors
Paul A. Renhowe et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Design, Synthesis, and Evaluation of Indolinones as Triple Angiokinase Inhibitors and the Discovery of a Highly Specific 6-Methoxycarbonyl-Substituted Indolinone (BIBF 1120)
Gerald J. Roth et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
The FGF family: biology, pathophysiology and therapy
Andrew Beenken et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy
Frank Hilberg et al.
CANCER RESEARCH (2008)
Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation
KM Sakamoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
分享论文
